Methazolamide — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	2-4 mg/kg	q8-12h	Duration: Long-term as needed for glaucoma Notes: Dose may be adjusted based on intraocular pressure response. Monitor for metabolic acidosis.
Cat	PO	2-4 mg/kg	q8-12h	Duration: Long-term as needed for glaucoma Notes: Cats may be more sensitive to adverse effects; use with caution.
Horse	PO	2-4 mg/kg	q12h	Duration: As needed Notes: Limited data; use with caution.
Rabbit	PO	2-4 mg/kg	q12h	Duration: As needed Notes: Limited data; use with caution.

Clinical Indications & Species Uses

General Indications

Reduction of intraocular pressure in glaucoma
Treatment of metabolic alkalosis (off-label)
Adjunctive therapy for certain types of edema (off-label)

Dog (Canine)

Treatment of glaucoma (open-angle and secondary) to reduce intraocular pressure
Adjunctive therapy for uveitis-associated glaucoma
Management of hydrocephalus (off-label)

Cat (Feline)

Treatment of glaucoma (primary and secondary) to reduce intraocular pressure
Adjunctive therapy for uveitis-associated glaucoma

Pharmacology & Mechanism of Action

Drug Class: Carbonic anhydrase inhibitor | Pharmacological Group: Sulfonamide derivative

Mechanism of Action: Methazolamide is a carbonic anhydrase inhibitor that reversibly inhibits the enzyme carbonic anhydrase, which catalyzes the hydration of carbon dioxide and dehydration of carbonic acid. In the eye, inhibition of carbonic anhydrase in the ciliary processes reduces the formation of aqueous humor by decreasing bicarbonate and sodium transport, thereby lowering intraocular pressure. It also has systemic effects, including metabolic acidosis and increased urinary bicarbonate excretion, which can be exploited in certain therapeutic contexts.

Pharmacodynamics: Methazolamide reduces intraocular pressure by decreasing aqueous humor production. It is more lipid-soluble than acetazolamide, allowing better penetration into ocular tissues and potentially fewer systemic side effects. It also produces a mild diuretic effect and can cause metabolic acidosis. The drug's effect on intraocular pressure is dose-dependent and typically peaks within 2-4 hours after oral administration.

⚡ Pharmacokinetics Summary

Absorption: Methazolamide is well absorbed after oral administration, with peak plasma concentrations occurring within 1-2 hours. Food may delay absorption but does not significantly affect the extent.

Distribution: Methazolamide is widely distributed throughout the body, including the eye. It crosses the blood-brain barrier and placenta, and is distributed into milk. It has a higher lipid solubility than acetazolamide, which enhances its penetration into tissues.

Metabolism: Methazolamide is minimally metabolized in the liver; most of the drug is excreted unchanged in the urine. It undergoes some hepatic acetylation, but the extent is limited.

Excretion: Methazolamide is primarily excreted by the kidneys via glomerular filtration and tubular secretion. Renal excretion is pH-dependent; alkalinization of urine increases excretion. The elimination half-life is longer than acetazolamide, allowing less frequent dosing.

Half-Life: Dogs: approximately 8-14 hours; Cats: approximately 10-15 hours; Humans: 10-15 hours.

Bioavailability: Oral bioavailability is high, estimated at >90%.

Protein Binding: Approximately 55-60% bound to plasma proteins.

Available Formulations & Strengths

Oral Tablet 25 mg, 50 mg (PO)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to methazolamide or other sulfonamides
Severe hepatic or renal impairment
Adrenal insufficiency
Electrolyte imbalance (e.g., hyponatremia, hypokalemia)
Concurrent use with high-dose salicylates (risk of metabolic acidosis and salicylate toxicity)

Warnings & Clinical Precautions:

Use with caution in patients with respiratory acidosis or chronic obstructive pulmonary disease.
May cause metabolic acidosis; monitor acid-base status during prolonged therapy.
Use with caution in pregnant or lactating animals; safety not established.
May cause drowsiness or lethargy; monitor for behavioral changes.
In animals with glaucoma, use as an adjunct to topical therapy; not a substitute for surgical intervention if needed.
Monitor renal function and electrolytes periodically.

Adverse Effects & Reactions

Common:

Polyuria
Polydipsia
Anorexia
Vomiting
Diarrhea
Lethargy
Metabolic acidosis

Serious / Severe:

Blood dyscrasias (e.g., aplastic anemia, thrombocytopenia)
Renal calculi
Hepatic necrosis
Stevens-Johnson syndrome
Severe electrolyte disturbances

Rare:

Paresthesia
Tinnitus
Transient myopia
Bone marrow suppression

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Salicylates (e.g., aspirin)	Increased risk of metabolic acidosis and salicylate toxicity due to decreased renal excretion of salicylates.	High
Corticosteroids	Additive hypokalemia and increased risk of metabolic acidosis.	Moderate
Amphotericin B	Increased risk of hypokalemia and nephrotoxicity.	Moderate
Lithium	Increased lithium excretion, reducing its efficacy.	Moderate
Phenytoin	Increased risk of osteomalacia and metabolic acidosis.	Mild
Primidone	Possible increased risk of metabolic acidosis.	Mild

Overdose & Toxicity Management

Signs of Toxicity:

Severe metabolic acidosis
Hyperventilation
Lethargy
Weakness
Tremors
Seizures
Coma

Emergency Treatment Protocol: Treatment is symptomatic and supportive. Induce vomiting if recent ingestion and animal is conscious. Administer activated charcoal to reduce absorption. Correct metabolic acidosis with intravenous sodium bicarbonate as needed. Monitor electrolytes, blood gases, and renal function. Provide fluid therapy to enhance excretion. In severe cases, consider hemodialysis.

Food Animal Withdrawal Times

Not approved for use in food animals; no withdrawal times established. Use in food animals is off-label and prohibited in some jurisdictions.

Storage, Handling & Regulatory Information

Storage Temperature: Store at room temperature (20-25°C, 68-77°F)

Handling & Special Conditions: Protect from moisture. Keep container tightly closed.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for human use; not FDA-approved for veterinary use, but may be used off-label in animals.

Extra-Label (Off-Label) Use: In the US, extra-label use in food animals is prohibited under AMDUCA if an approved animal drug exists that is labeled for the condition. Methazolamide is not approved for veterinary use in food animals; therefore, extra-label use in food animals is not permitted. In companion animals, extra-label use is allowed under veterinary discretion.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Methazolamide is a carbonic anhydrase inhibitor used primarily for the management of glaucoma in dogs and cats. It is an alternative to acetazolamide, with a longer duration of action and potentially fewer side effects. It is important to monitor intraocular pressure regularly and adjust dosing accordingly. Because it can cause metabolic acidosis, periodic monitoring of acid-base status and electrolytes is recommended, especially during long-term therapy. In animals with glaucoma, methazolamide is often used in combination with topical beta-blockers or other glaucoma medications. It is not a first-line treatment for acute glaucoma but may be used as an adjunct. In cases of refractory glaucoma, surgical options should be considered. Methazolamide should be used with caution in animals with renal or hepatic impairment, and in pregnant or lactating animals. Always consider the potential for drug interactions, particularly with salicylates and corticosteroids. For food animals, this drug is not approved and should not be used due to lack of withdrawal data and potential residues.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)